Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
Information source: Aristotle University Of Thessaloniki
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type II Diabetes Mellitus
Intervention: Rosiglitazone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Aristotle University Of Thessaloniki Official(s) and/or principal investigator(s):
Christos Liapis, PhD,MD, Study Chair, Affiliation: University of Athens,Greece
Summary
The aim of the present study is to investigate the influence of systemic exercise,
rosiglitazone administration and combined pharmaceutical and lifestyle intervention on
cardiovascular risk factors
Clinical Details
Official title: Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Cardiovascular risk factors alterations
Eligibility
Minimum age: 40 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Type II diabetes mellitus
- Poor glycemic control
Exclusion Criteria:
- Heart failure
- Renal disease
- Liver disease
- Cardiovascular event
Locations and Contacts
AHEPA University Hospital of Thessaloniki, Thessaloniki 54454, Greece
Additional Information
Starting date: January 2005
Ending date: October 2006
Last updated: April 3, 2007
|
